

This is the **published version** of the journal article:

Jiménez-López, Jesús [et al.]. «Pacing system analyzers to guide conduction system pacing implantation procedures : A comparison study of intracardiac and surface signals with an electrophysiology recording system». *Heart Rhythm*, 2025. DOI 10.1016/j.hrthm.2024.12.030

This version is available at <https://ddd.uab.cat/record/311313>

under the terms of the  ^{IN}COPYRIGHT license.

1 **Title: ‘Pacing System Analyzers to guide Conduction System Pacing implantation**
2 **procedures: A comparison study of intracardiac and surface signals with an**
3 **Electrophysiological Recording System’**

4 Jesús Jiménez-López^{1*} MD, Carlos E. González-Matos^{1,2} MD, Oriol Rodríguez-Queraltó¹ MD-PhD, Jaume
5 Francisco-Pascual³ MD-PhD, Nisha Lal-Trehan Estrada³ MD, Gabriel Martín-Sánchez⁴ MD, Sandra
6 Cabrera-Gómez⁴ MD, Manuel Molina Lerma MD-PhD⁵, Benjamín Casteigt¹ MD, Jordi Mercè-Klein⁶ MD-
7 PhD, Marcos A. Rodríguez-García⁶ MD-PhD, Eva Benito-Martín⁷ MD, Javier Conejos-Montenegro⁷ MD,
8 Jorge Luis Rodríguez Garrido⁸ MD, Juliana Elices Teja⁹ MD, Pau Cosialls Guillen^{1¥} MSc, Aitor Toledo
9 Silva^{1σ} MSc, Carolina López Reitmaier^{1φ} MSc, Ermengol Vallès Gras^{1,2} MD-PhD.

10 ¹ Electrophysiology Unit. Cardiovascular Division. Hospital del Mar. Passeig Marítim de la Barceloneta.
11 Barcelona. Spain.

12 ² Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.

13 ³Unitat d’arrítmies. Cardiology Department. University Hospital Vall d’Hebrón and Vall d’Hebron
14 Research Institute. Autonomous University of Barcelona. CIBER-CV. Barcelona. Spain

15 ⁴ Arrhythmia Unit. Cardiovascular Division. University Hospital Joan XXIII. Tarragona. Spain.

16 ⁵ Arrhythmia Unit. Hospital Virgen de las Nieves. Granada. Spain.

17 ⁶ Arrhythmia Unit. Heart Disease Institute Bellvitge University Hospital. Barcelona. Spain.

18 ⁷ Arrhythmia Unit. University Hospital Doctor Trueta. Girona. Spain.

19 ⁸ Electrophysiology Unit. Cardiology department. Complejo Hospitalario Universitario A Coruña. A
20 Coruña. Spain.

21 ⁹ Arrhythmia Unit. Cardiology Department. Hospital Lucus Augusti. Lugo. Spain.

22 [¥]Abbott Medical Engineer; ^σBoston Scientific Engineer; ^φMedtronic Engineer

23
24 Running title: ‘Pacing System Analyzers to guide Conduction System Pacing implantation procedures’

25
26 Word account: 4843

27 * Author for correspondence: Jesús Jiménez López, MD. Unidad de Arritmias. Hospital del Mar. Adress:
28 25-27 Passeig Marítim, Barcelona, 08003 Spain.

29 **Conflicts of interest:** This publication has received no external financial support. All the authors of this
30 manuscript have declared that no competing interests exist.

31
32 **ABSTRACT**

33 **Background:** Left bundle branch area pacing (LBBAP) needs confirmation of left
34 conduction system capture assessed by testing of different electrical parameters.
35 Guidelines recommend the use of an electrophysiological recording-system (EP-RS) to
36 guide conduction system pacing (CSP) procedures. However, some experienced centers
37 perform LBBAP procedures without an EP-RS.

38 **Objective:** We aimed to assess whether LBBAP criteria can be measured using the
39 signals provided by the pacing system analyzers (PSA) as a surrogate for the EP-RS to
40 simplify and universalize the technique.

41 **Methods:** This was an observational, prospective, multicenter study assessing the current
42 LBBAP criteria using the PSA compared to the EP-RS during CSP procedures.

43 **Results:** 108 consecutive patients were included. Baseline QRS duration was 130 ± 29 vs
44 128 ± 29 msec in the EP-RS vs PSA ($p=0.7$). An initial “W” morphology in V1 was noted
45 in 88% patients with the EP-RS vs 86% patients with the PSA ($p=0.7$) during unipolar
46 pacing. The QRS duration (122 ± 17 vs 123 ± 19 msec, $p=0.7$), the R-wave peak time
47 interval in V6 (80 ± 13 vs 79 ± 14 msec ($p=0.9$) and the V6-V1 inter-peak interval (39 ± 16
48 vs 38 ± 17 msec ($p=0.7$) were superimposable in the EP-RS compared to the PSA. Pearson
49 coefficient for the last two criteria were 0.85 ($p<0.0001$) and 0.94 ($p<0.0001$),
50 respectively. According to the current criteria, 91.5% of patients received a successful
51 LBBAP implant using the EP-RS. Based on the PSA measurements, 96.6% of these
52 patients accomplished LBBAP criteria.

53 **Conclusions:** Criteria for LBBAP can be assessed by PSAs with high accuracy. These
54 results provide the basis for the usefulness of the PSA to guide LBBAP procedures.

55 **KEYWORDS**

56 Conduction system pacing; Left bundle branch area pacing; Electrophysiological
57 recording system; Pacing system analyzer; Surface Electrocardiogram leads.

58

59

ABBREVIATIONS LIST

60

61 CSP: Conduction system pacing.

62 ECG: Electrocardiogram.

63 EGM: Electrogram.

64 EP-RS: Electrophysiological recording system.

65 LBBAP: Left bundle branch area pacing.

66 LBBP: Left bundle branch pacing.

67 PSA: Pacing system analyzer.

68 V6-RWPT: V6 R wave peak time.

69 V6-V1 IPT: V6-V1 inter-peak time.

70

INTRODUCTION

71

72 Conduction System Pacing (CSP) involves implantation of permanent pacing leads along
73 different sites of the cardiac conduction system¹. Nowadays, CSP is mostly performed by
74 left bundle branch area pacing (LBBAP)^{2,3}, due to its advantages compared to His bundle
75 pacing⁴. Several criteria have been described to assess the appropriate capture of the left
76 bundle^{5,6}, including intracardiac electrograms (EGM), as well as different morphology
77 and duration 12-lead electrocardiogram (ECG) criteria. Currently, LBBAP procedures
78 are mainly performed in centers where an electrophysiology recording system (EP-RS)
79 is available to assess the above-mentioned criteria. However, pacing system analyzers
80 (PSA) are capable of displaying intracardiac EGMs and several ECG surface leads. The
81 performance of the PSA to assess the accomplishment of LBBAP criteria compared to
82 EP-RS has never been previously studied.

83

METHODS

84

85 All patients provided written informed consent before undergoing the implantation
86 procedure. The study was approved by the Institutional Review Board (Ethics-Committee
87 approval no. 2023 /10850/I and registered in Clinicaltrials.gov (ID) NCT06371846) and
88 was compliant with the declaration of Helsinki as revised in 2013.

89

Study objectives, protocol and data collection

91 Our aim was to assess the LBBAP criteria using the signals from the PSA, compared to
92 the gold standard EP-RS signals, during CSP implantation procedures.

93 This was an observational, prospective, multicentric study. From March/2023 to
94 May/2024, consecutive patients undergoing a LBBAP implantation procedure were
95 enrolled from eight different participating centers in Spain.

96 Baseline characteristics including demographics, pacing indication, baseline ECG
97 characteristics and cardiac ultrasound parameters, were collected. From the implantation
98 procedure, total and fluoroscopy time, acute thresholds, and baseline and final paced ECG
99 parameters, including the stimulated QRS (S-QRS) morphology and duration, the V6 R
100 wave peak time (V6-RWPT), the V6-V1 inter-peak time (V6-V1 IPT) and changes
101 between selective and non-selective LBBP, were collected, among others. Complications
102 occurring during the first 24 hours were all documented.

103

104 **Recording of precordial leads and measurements with the PSA**

105 The PSA leads were placed as explained:

106 Briefly, we modified the Mason-Likar electrode lead placement to record V1 and V6. In
107 PSAs with bipolar configuration, we placed the reference electrode (right arm) of leads I
108 and II on the back, and the exploring electrodes (left arm and left leg) adjacent to V1 and
109 V6. In PSAs with unipolar configuration, we placed the additional unipolar electrode
110 adjacent to V1 and moved down the exploring electrode of lead aVL (left arm) adjacent
111 to V6.

112 The pacing artifact location and the corresponding voltage/time curve representation, as
113 well as the marker channel, depend on each PSA software characteristics. To simplify the
114 measurement process and to avoid differences between PSA manufacturers (Figure 1),
115 we considered the beginning of all measurements at the initial deflection of the pacing

116 artifact on the surface ECG channels while unipolar stimulation at the lowest output
117 capturing the ventricle (see ‘Signals Optimization’ in supplementary material).

118

119 **Procedure preparation and implantation**

120 All patients underwent a LBBAP implantation procedure as follows. Briefly, the 12-leads
121 ECG and one channel with intracardiac EGMs were displayed in the EP-RS for
122 measurements and criteria assessment. The bipolar +/- unipolar PSA ECG surface leads
123 were placed as previously described. The duration and morphology characteristics of
124 baseline QRS corresponding to V1-V6 in the PSA were compared to those with the EP-
125 RS to confirm the correct position of the PSA electrodes.

126 Operators mainly used an anatomic approach, aiming for a “W” pattern in V1 during
127 unipolar stimulation. A non-styilet active fixation 4F lead or a styilet-driven active fixation
128 6F lead was implanted using an appropriate dedicated CSP sheath. The pacing lead
129 position was reassessed in posteroanterior, right anterior oblique and left anterior oblique
130 projections. The pacing electrode was then screwed in guided by a moderate drop in the
131 unipolar impedance, the achievement of a small q wave in the current of injury, and the
132 conversion of the “W” in V1 into a qR or rSR pattern. LBBP criteria were then evaluated
133 during unipolar pacing. Lastly, thresholds were obtained, both in unipolar and bipolar
134 configuration. Bipolar EGMs on the EP-RS were filtered through a band-pass of 30-
135 500Hz at a speed of 100mm/s and a gain of 0.1mV/cm. In the PSA, signals were
136 optimized and displayed at a speed range between [50-100] mm/sec and at gain of 0.5-1
137 mm/mV. Intracardiac EGMs, paced QRS duration, measured from the QRS onset and
138 from the stimulation artifact (S-QRS), QRS morphology, V6-RWPT, and V6-V1 IPT
139 were obtained simultaneously at the operator’s discretion in both systems. The EP-RS

140 signals were analyzed and measured by an expert electrophysiologist from the control
141 room and served to guide the LBBAP lead implantation. The PSA signals were recorded
142 and measured by a dedicated engineer in the operating room solely for the purpose of
143 comparing them with the EP-RS signals at separate analysis. The electrophysiologist in
144 the control room and the engineer in the operating room were blinded to each other
145 (Supplemental Figure 1). After the implantation procedure, all these measurements were
146 validated by two independent electrophysiologists of each participating center.

147

148 **Definitions**

149 Following recent step-by-step recommendations⁸, LBBP was defined as conclusive in the
150 presence of at least one of the following criteria:

- 151 1. QRS transition from non-selective LBBP to selective LBBP or non-selective
152 LBBP to left ventricular septal pacing during pacing threshold.
- 153 2. V6-RWPT interval <75 msec in patients with narrow QRS or <80 msec in
154 patients with left bundle branch block, interventricular conduction disturbances,
155 right bundle branch block + fascicular block, wide escape rhythm, or asystole.
- 156 3. V6–V1 IPT >44 msec.
- 157 4. CS potential to V6-RWPT = stimulation artifact to V6-RWPT (± 10 msec).

158 In addition, LBBP was defined as likely in the following situations:

- 159 1. V6-RWPT interval between 75-85 msec (native narrow QRS or isolated
160 right bundle branch block) or V6RWPT between 80-100 msec in patients
161 with left bundle branch block, interventricular conduction disturbances, right
162 bundle branch block + fascicular block, wide escape rhythm, or asystole).
- 163 2. V6–V1 IPT between 33-44 msec.

164 3. QRS transition from CS potential (selective or non-selective) capture to
165 myocardial only capture associated with V6-RWPT prolongation by 10-
166 14ms.

167

168 Left ventricular septal pacing was defined by a S-QRS showing a typical terminal R wave
169 in V1, and anatomical position of the lead in the interventricular septum documented by
170 fluoroscopy, but not fulfilling the criteria previously described for LBBP. Deep septal
171 pacing was defined by absence of terminal R-wave in V1, despite having an anatomical
172 position of the lead deep in the interventricular septum.

173

174 **Monitoring and discharge**

175 Patients were discharged after an observation period of at least 24 hours and after the
176 performance of a 12-lead ECG, an X-ray, and a device interrogation.

177

178 **Statistical Analysis**

179 Data were expressed as mean \pm SD or number of cases and proportions according to the
180 variable type (continuous or discrete). Normality was tested using the Shapiro-Wilk test.
181 The T-test was used to assess continuous variables. The Z test was used to compare
182 discrete variables. Pearson and Spearman correlation coefficients were employed as
183 appropriate for measurements correlation analysis as well as Bland-Altman analysis for
184 continuous variables. Indirect comparison of correlation coefficients was performed
185 using the Fisher R to Z transformation. Statistical analysis was performed using STATA,
186 version 15.1 for Windows (StataCorp LLC, College Station, TX).

187

188

RESULTS

189

190 **Demographic characteristics**

191 One hundred and eight patients were included. Baseline characteristics of the patients are
192 shown in Table 1. Briefly, the mean age was 72 ± 15 years, with clear predominance of
193 the male sex, and presenting more than 50% of the population structural heart disease.
194 Intraventricular conduction disorders were observed in most of the patients, and it should
195 be noted that the main indication for cardiac pacing in more than half of the patients was
196 the development of a high degree atrioventricular block.

197

198 **Intraprocedural characteristics**

199 Out of the total, 73% of patients received a dual chamber pacemaker and 23% received a
200 single chamber pacemaker. In 4% of patients, the original indication was cardiac
201 resynchronization therapy device, but a LBBAP procedure was decided after failure of
202 coronary sinus cannulation. The percentage of the different PSA employed during the
203 procedure was as follows: Abbott 40%, Medtronic 31%, Boston Scientific 15% and
204 Biotronik 14%. Average skin-to-skin procedure time, LBBAP electrode implantation
205 time, and fluoroscopy time were 80 ± 23 , 27 ± 23 , and 7.5 ± 5 minutes, respectively. A
206 steerable sheath was used in 8% of the patients and contrast injection was employed in
207 14% of the patients. A non-stylet active fixation 4F lead was implanted in 43% of the
208 patients.

209

210 **QRS measurements**

211 At the beginning of the procedure, no significant differences ($p=0.7$) were observed in
212 the baseline QRS duration when comparing the EP-RS (130 ± 29 msec) and the PSA
213 (128 ± 29 msec) (Table 2).

214 A "W" morphology was observed during initial pacing in V1 in 88% vs 86% of patients
215 using the EP-RS vs the PSA ($p=0.7$). A conduction system potential was documented
216 during the procedure in 24.5% vs 21.2% of the patients with the EP-RS vs the PSA
217 ($p=0.56$).

218 In patients accomplishing LBBP criteria (definitive or likely), a "qR" or "rSR"
219 morphology in V1 was observed in 77% with the EP-RS compared to 75% with the PSA
220 ($p=0.77$). Regarding specific criteria, the V6-RWPT was 80 ± 13 vs 79 ± 14 msec ($p=0.9$),
221 and the V6-V1 IPT was 39 ± 16 vs 38 ± 17 msec ($p=0.7$), with the EP-RS vs the PSA, being
222 the Pearson correlation coefficients for these two last measurements 0.85 ($p<0.0001$) and
223 0.94 ($p<0.0001$), respectively (Figure 2) (See Supplemental Table 1). An "rS" pattern in
224 V6 during pacing was observed in 12 patients (11,3%). Eight of these patients were
225 assigned to LVSP because they did not meet other specific LBBP criteria.

226 LBBP criteria (definitive or likely), LVSP criteria, and DSP criteria were fulfilled in
227 76.4%, 15.1% and 8.5% of patients respectively, assessed by EP-RS. When comparing
228 LBBAP criteria based on EP-RS vs PSA measurements, we observed an excellent
229 correlation (Spearman correlation coefficient of 0.97). QRS transition during stimulation
230 was employed to confirm LBBAP in 18.6% of the patients (assessed by EP-RS), without
231 differences between both systems. The V6-RWPT and the V6-V1 IPT were the most
232 frequent criteria employed to confirm LBBAP capture (81.4% in the EP-RS vs 80.4% in
233 the PSA), with a global correlation coefficient of 0.96 ($p < 0.0001$) (Figure 3 and 4).

234 The S-QRS averaged 144 ± 15 msec with the EP-RS, vs 143 ± 17 msec with the PSA
235 ($p=0.5$), with a Pearson correlation coefficient of 0.83 ($p<0.0001$); the QRS duration from
236 the QRS onset averaged 122 ± 17 msec with the EP-RS, vs 123 ± 19 msec with the PSA
237 ($p=0.7$), with Pearson correlation coefficient of 0.81 ($p<0.0001$). The Bland-Altman plot
238 for the analysis of baseline QRS duration, V6-RWPT interval, V6-V1 IPT and paced-
239 QRS duration rendered non-significant bias (Figure 5).

240 Analysis of each PSA separately showed significant correlation in most of the
241 measurements as compared with the EP-RS (Supplemental Tables 2-5). Indirect
242 comparisons of the correlations coefficients (with Fisher r to z transformation) between
243 the different PSA did not render superiority of any specific system over the others
244 (Supplemental Tables 6-6'). In addition, there was no superiority in the unipolar vs bipolar
245 PSA configuration comparison (Supplemental Tables 7-9).

246 Considering the absence of previous data on acceptable differences between EP-RS and
247 PSA measurements in the context of the present study, a post-hoc power calculation
248 was performed, setting the EP-RS measurements as a reference, in order to detect
249 10msec or 10% differences, as appropriate (Supplemental Table 10).

250

251 **Learning curve**

252 Learning curves, addressed by quadratic regression for different variables, rendered a
253 plateau after performing less than 30 procedures (Supplemental Figures 2-4). Absolute
254 differences of less than 5 msec were observed in the measurements between both systems
255 after performing the first 10 procedures. The reduction in the lead placement time was
256 progressive, reaching times of less than 20 minutes after the first 20 cases.

257

DISCUSSION

258

259 The main finding of this study is the usefulness of the PSA as a simple and reliable
260 alternative tool to guide CSP implantation procedures, which can accurately provide
261 similar information compared to EP-RS (comparable intracardiac EGM, surface ECG
262 leads, and time-calipers).

263 We propose a new technique to obtain V1 and V6 PSA leads, analogous to those
264 displayed by the EP-RS, in a simple and standardized manner. No differences were
265 observed in the measurements obtained by any individual PSA compared to each other
266 or when comparing all PSAs with unipolar/bipolar configuration to the EP-RS. These
267 results suggest that a standardized configuration could be used for all the PSAs
268 (Supplementary material Figure 5).

269 Although current guidelines highly recommend the use of an EP-RS to guide CSP
270 implantation procedures, not all the centers, even the most experienced, have an EP-RS
271 available. This scenario should not be a major limitation to perform CSP procedures. In
272 fact, a study from the Working Group of Pacing and Electrophysiology of the French
273 Society of Cardiology⁹ based on an online survey showed that the absence of an EP-RS
274 available in the lab was perceived as a limitation only in 14% of respondents.

275 Recently, Wang M et al¹⁰ have shown for the first time the effectiveness and feasibility
276 of LBBAP performance combining a multi-lead surface ECG monitoring and the
277 intracardiac EGMs from the PSA. In this regard, new portable devices capable of
278 displaying a virtual 12-lead ECG and including time-calipers could be of interest for
279 future research. However, these devices do not include intracardiac EGMs. Instead, we
280 propose the PSA as a universal alternative method, which uses two surface ECG leads
281 combined with the intracardiac EGMs.

282 Considering that most of the ECG criteria assessing LBBAP rely on QRS morphology
283 and/or time intervals using V1 and V6 leads, this new approach could highly simplify the
284 standard approach. Thus, this method is able even to display slight differences in the QRS,
285 offering the possibility to observe progressive reduction in V6-RWPT and/or lengthening
286 in V6-V1 IPT with stimulation during the lead rotations¹¹. In fact, these two criteria were
287 the most used to assess LBBAP in our study, in line with routine clinical practice^{12,13},
288 showing an excellent correlation between EP-RS and PSA. Other criteria (i.e. transition
289 in the QRS morphology), were also observed in the same proportion with both methods
290 and in a similar proportion to previous studies¹⁴. In contrast with our proposed approach,
291 a 12-leads ECG can further predict the final altitudinal position of the pacing-lead (i.e.
292 pure left bundle vs left posterior or left anterior fascicles capture). However, a recent
293 study concluded that, in patients with heart failure and complete left bundle branch block,
294 LBBP on the trunk or a specific fascicle, can achieve similar favorable QRS complex
295 narrowing, cardiac function improvement, and cardiac reverse remodeling¹⁵.

296 Overall, we found a 96.4% concordance during the assessment of LBBAP criteria for the
297 final lead location comparing both methods, suggesting that the use of the PSA is feasible
298 and useful during CSP implantation procedures. This simplified approach could probably
299 facilitate the performance of LBBAP implantation procedures in different scenarios (i.e.:
300 urgent pacemaker implantation procedures) and spread the technique to more centers (i.e.
301 centers without an EP-RS available).

302 Finally, the learning curves show that only a few cases are needed in order to achieve
303 similar measurements with the PSA compared to the EP-RS. In addition, the reduction in
304 the lead placement time after the first 20 cases is similar to previous studies¹⁶.

305 Although all the main investigators were highly experienced electrophysiologists and
306 participant centers had a high volume of CSP procedures, from these results we can

307 conclude that this approach could be useful for centers without an EP-RS or with a low
308 experience in CSP procedures.

309

310 **Suggested Step-by-Step recommendations for simplified PSA approach:**

- 311 - To check baseline V1 and V6 EP-RS leads vs PSA leads for quality control.
- 312 - To set the speed rate on the PSA at 25 or 50 mm/sec to identify the initial ‘W’ pattern
313 (Figure 6 in supplementary material) or the paced right bundle branch morphology
314 pattern. Thereafter a speed rate of 100 mm/sec will improve QRS measurements.
315 Alternatively increase the gain.
- 316 - Visualization of CS potentials could be challenging specially during stimulation, due to
317 differences in the filters and software of the PSA. It is recommended to take into account
318 any pre-QRS intracardiac EGMs, independently of its frequency and/or voltage (see
319 Figure 7 in Supplementary material).

320

321

LIMITATIONS

322 This was a non-randomized multicenter study. Although patients were consecutively
323 enrolled, a selection bias cannot be ruled out. The sample size was not calculated before
324 starting the study. However, a post-hoc analysis rendered high power to detect significant
325 differences between the EP-RS/PSA measurements. The main investigator of each center
326 was responsible for the final measurements reviewed, so an observer bias in the results
327 cannot be excluded. The absence of significant differences between the different PSAs
328 could be related to the small sample size. Studies with larger cohorts of patients would be
329 needed. Because these two approaches have not been directly compared, a comparative

330 trial evaluating the efficacy and accuracy of using PSA signals alone versus EP-RS
331 signals could provide insightful data.

332

333 **CONCLUSIONS**

334 These results suggest that a simplified PSA approach focusing on specific measurements
335 could be feasible and useful for LBBAP procedures as compared to current approach with
336 the EP-RS.

337

338 **Acknowledgements**

339 The authors would like to thank the Department of Medicine, Universitat Autònoma de
340 Barcelona, for their support of PhD studies of Dr González-Matos. They also thank the
341 patients who have made this work possible.

342

343 **Data availability statement:**

344 All relevant data are within the manuscript and its Supporting Information files.

345

346

347

348

349 **REFERENCES**

- 350 1.- Jastrzebski M, Dandamudi G, Burri H, Ellenbogen KA. Conduction system pacing:
351 overview, definitions, and nomenclature. *Eur Heart J Suppl.* 2023 Nov 9;25(Suppl G):G4-
352 G14. doi: 10.1093/eurheartjsupp/suad114. PMID: 37970514; PMCID: PMC10637837.
- 353 2.- Wu S, Sharma PS, Huang W. Novel left ventricular cardiac synchronization: left
354 ventricular septal pacing or left bundle branch pacing? *Europace.* 2020 Dec
355 26;22(Suppl_2): ii10-ii18. doi: 10.1093/europace/euaa297. PMID: 33370804.
- 356 3.- González-Matos CE, Rodríguez-Queralto O, Záraket F, et al. Conduction System
357 Stimulation to Avoid Left Ventricle Dysfunction. *Circ Arrhythm Electrophysiol.*
358 2024;17(2): e012473. doi: 10.1161/CIRCEP.123.012473. Epub 2024 Jan 29. PMID:
359 38284238.
- 360 4.- Yuan Z, Cheng L, Wu Y. Meta-Analysis Comparing Safety and Efficacy of Left
361 Bundle Branch Area Pacing Versus His Bundle Pacing. *Am J Cardiol.* 2022 (1);164:64-
362 72. doi: 10.1016/j.amjcard.2021.10.025. Epub 2021 Dec 7. PMID: 34887071.
- 363 5.- Briongos-Figuero S, Estévez-Paniagua Á, Sánchez-Hernández A, et al. Tailored
364 electrocardiographic-based criteria for different pacing locations within the left bundle
365 branch. *Heart Rhythm.* 2024 ;21(1):54-63. doi: 10.1016/j.hrthm.2023.09.015. Epub 2023
366 Sep 21. PMID: 37741525.
- 367 6.- Pujol-López M, Ferró E, Borràs R, et al. Stepwise application of ECG and
368 electrogram-based criteria to ensure electrical resynchronization with left bundle branch
369 pacing. *Europace.* 2023 2;25(6): euad128. doi: 10.1093/europace/euad128. PMID:
370 37294671; PMCID: PMC10254073.
- 371 8.- Burri H, Jastrzebski M, Cano Ó, et al. EHRA clinical consensus statement on
372 conduction system pacing implantation: endorsed by the Asia Pacific Heart Rhythm

373 Society (APHRS), Canadian Heart Rhythm Society (CHRS), and Latin American Heart
374 Rhythm Society (LAHRS). *Europace*. 2023;25(4):1208-1236. doi:
375 10.1093/europace/euad043. PMID: 37061848; PMCID: PMC10105878.

376 9.- Ollitrault P, Chaumont C, Font J, et al. Conduction system pacing in France in 2022:
377 A snapshot survey from the Working Group of Pacing and Electrophysiology of the
378 French Society of Cardiology. *Arch Cardiovasc Dis*. 2023;116(5):265-271. doi:
379 10.1016/j.acvd.2023.04.004. PMID: 37179224.

380 10.- Wang M, Sun Y, Shan Y, et al. The effectiveness and feasibility of using multi-lead
381 ECG monitoring combined with a programmed intracavitary ECG to complete left bundle
382 branch area pacing. *Pacing Clin Electrophysiol*. 2023;46(3):205-216. doi:
383 10.1111/pace.14676. Epub 2023 Mar 1. PMID: 36788130.

384 11.- Jastrzębski M, Kielbasa G, Moskal P, et al. Transseptal Transition Patterns
385 During Left Bundle Branch Area Lead Implantation. *JACC Clin Electrophysiol*. 2024
386 Sep 16:S2405-500X(24)00754-0. doi: 10.1016/j.jacep.2024.07.025. Epub ahead of print.
387 PMID: 39387738.

388 12.- Vijayaraman P, Ponnusamy S, Cano Ó, et al. Left Bundle Branch Area Pacing for
389 Cardiac Resynchronization Therapy: Results From the International LBBAP
390 Collaborative Study Group. *JACC Clin Electrophysiol*. 2021 Feb;7(2):135-147. doi:
391 10.1016/j.jacep.2020.08.015. Epub 2020 Oct 28. PMID: 33602393.


392 13.- Keene D, Anselme F, Burri H, et al. Conduction system pacing, a European survey:
393 insights from clinical practice. *Europace*. 2023;25(5):euad019. doi:
394 10.1093/europace/euad019. PMID: 36916199.

395 14.- Jastrzębski M, Kielbasa G, Cano O, et al. Left bundle branch area pacing outcomes:
396 the multicentre European MELOS study. *Eur Heart J.* 2022;43(40):4161-4173. doi:
397 10.1093/eurheartj/ehac445. PMID: 35979843; PMCID: PMC9584750.

398 15.- Liu W, Fulati Z, Tian F, et al. Relationship of different left bundle branch pacing
399 sites and clinical outcomes in patients with heart failure. *Heart Rhythm.* 2024 Sep
400 2:S1547-5271(24)03285-5. doi: 10.1016/j.hrthm.2024.08.059. Epub ahead of print.
401 PMID: 39233256.

402 16.- Cano Ó, Jover P, Ayala HD, et al. Left bundle branch pacing versus left ventricular
403 septal pacing as a primary procedural endpoint during left bundle branch area pacing:
404 Evaluation of two different implant strategies. *J Cardiovasc Electrophysiol.* 2024
405 Jan;35(1):120-129. doi: 10.1111/jce.16128. Epub 2023 Nov 14. PMID: 37962088.

406




408

409 **Figure 1- A to D.-** Different ventricular EGMs, marker channels, and their relation with
 410 the surface ECG signals. The rationale of using the pacing artifact of the surface ECG is
 411 based on the different relationship between the initial pacing artifact of the intracardiac
 412 EGM channels compared to the surface ECG signals. **A.-** Biotronik PSA: the ventricular
 413 channel is usually oversaturated. **B1-2.-** Abbott PSA: in the marker channel, VP is
 414 observed before a small initial (negative or positive) deflection. This deflection
 415 corresponds to a blanking window in the ventricular channel so that stimulation can be
 416 delivered. **C.-** Boston Scientific PSA: the marker channel matches with the initial pacing
 417 artifact of the surface ECG, due to its software characteristics. However, the initial
 418 deflection of the pacing stimulus is always located after the onset of the QRS complex.
 419 **D1-2.-** Medtronic PSA: the ECG input signal and the EGM/Marker signal are coming
 420 from two unique input sources. These two sources are independently processed by two
 421 different processing units. An algorithm gradually adjusts the waveform alignment to
 422 achieve a more time aligned view of the two different sources. The degree of temporal
 423 alignment of the two inputs can differ based on a variety of factors inherent in the input
 424 systems. EGM: ventricular electrogram.

425

426



427


428 **Figure 2.** Pearson correlations coefficient analysis shows a strong correlation of
 429 measurements between the PSA and the EP-RS. **A.** Baseline QRS duration (msec). **B.**
 430 V6-RWPT (msec). **C.** V6-V1 IPT (msec). **D.** S-QRS (Only QRS) duration (msec). EP-
 431 RS: Electrophysiological recording system. PSA: Cardiac pacing analyzer. S-QRS: Paced
 432 QRS duration. V6-RWPT: V6 R-Wave peak time. V6-V1 IPT: V6-V1 inter-peak time.

433

434

435

436




437

438 **Figure 3.** Comparison of EP-RS to PSA tracings during a LBBAP procedure in a patient
 439 with intact intraventricular conduction. Panel **A** shows baseline preprocedural tracings.
 440 To the left, and from top to bottom: Limb leads, distal unipolar intracardiac EGM, and
 441 precordial leads from the EP-RS. To the right, and from top to bottom, the corresponding
 442 PSA tracings of: V1, V6, and distal unipolar intracardiac EGM. QRS duration is displayed
 443 and is similar with both methods. Panel **B** shows final position S-QRS with V6-RWPT
 444 displayed and compared; and Panel **C** shows final position S-QRS with QRS duration
 445 displayed and compared.

446

447

448



449


450 **Figure 4.** Comparison of EP-RS to PSA tracings during a LBBAP procedure in a patient
 451 with left bundle branch block, with emphasis on the PSA QRS morphologies and
 452 measurements. Panel **A** shows baseline QRS duration. Panel **B** shows V6-RWPT. Panel
 453 **C** shows final S-QRS duration.

454

455

456

457



458

459 **Figure 5.** Bland-Altman plots showing non-significant differences between the PSA and
 460 EP-RS measurements (Red line: 95% Limits of agreement. Blue dashed line: Mean bias.
 461 Gray lines: 95% bias confidence interval). **A.** Baseline QRS duration (msec). **B.** V6-
 462 RWPT (msec). **C.** V6-V1 IPT (msec). **D.** S-QRS (Only QRS) duration (msec). EP-RS:
 463 Electrophysiological recording system. LOA: 95% Limits of agreement. PSA: Cardiac
 464 pacing analyzer. S-QRS: Paced QRS duration. V6-RWPT: V6 R-Wave peak time. V6-
 465 V1 IPT: V6-V1 inter-peak time.

466

467

468

Table 1. Baseline patients' characteristics

Variable	Total group (n 108)
Age (Years \pm SD)	72 \pm 15
Male sex (%)	73
Structural heart disease (%)	52
Ischemic	34
Dilated	29
Valvular	23
Others	14
QRS morphology (%)	
RBBB / LBBB	45 / 37
Non-specific	16
Normal QRS	2
Atrial fibrillation (%)	37
Paroxysmal	47
Permanent	53
LVEF (% \pmSD)	53 \pm 10
Procedure indication (%)	
High degree AV block	56
Sinus node disease	14
Atrial fibrillation (slow ventricular response or before AV node ablation)	11
Others	19

Atrioventricular. LBBB: Left bundle Branch block. RBBB: Right bundle Branch block. SD: Standard deviation. SHD: Structural heart disease.

Table 2. Comparison between EP-RS and PSA during the LBBAP procedure

Variable	EP-RS values	PSA values	Mean difference (95% CI)	P	Correlation coefficient	P	Mean bias (95% CI)	95% Limits of agreement
Intraprocedural measurements								
Baseline QRS (msec) ± SD	129.8 ± 29.4	128.3 ± 28.7	1.5 (-6.4 to 9.5)	0.70	0.96	<0.0001	1.26 (-0.3 to 2.8)	-14.2 to 16.7
Initial “W” in V1(%)	88	86.2		0.71	0.85	<0.0001		
CS Potential (%)	24.5	21.2		0.56	0.84	<0.0001		
Final qR/rSR V1 (%)*	77	75.3		0.77	0.92	<0.0001		
V6-RWPT (msec) ± SD	79.7 ± 13.5	79.5 ± 13.7	0.3 (-3.8 to 4.3)	0.90	0.85	<0.0001	0.3 (-1.3 to 1.8)	-14.1 to 14.6
V6-V1 IPT (msec) ± SD	39.4 ± 16.4	38.4 ± 17.4	1.1 (-4.3 to 6.4)	0.69	0.94	<0.0001	1.1 (-0.3 to 2.4)	-10.9 to 13.0
QRS duration (msec) ± SD	122.5 ± 17	123.4 ± 18.8	-1 (-6 to 4.1)	0.71	0.81	<0.0001	0.5 (-1.8 to 2.8)	-21.7 to 22.7
S-QRS (msec) ± SD	144.1 ± 15.1	142.8 ± 16.6	1.3 (-3.5 to 6.1)	0.58	0.83	<0.0001	1.7 (-0.3 to 3.8)	-16.3 to 19.8
Capture (%)								
LBBAP	91.5	92.4		0.80	0.94	<0.0001		
DSP	8.5	7.5						
LBBAP (%)								
Def LBBP	55.7	52.8		0.91	0.97	<0.0001		
Likely LBBP	20.8	26.4						
LVSP	15.1	13.2						

EP-RS: Electrophysiological recording system. CS: Conduction System. LBBAP: Left bundle branch area pacing. LBBP: Left bundle branch pacing. LVSP: left ventricular septal pacing. DSP: Deep septal pacing. Msec: milliseconds. PSA: Pacing system analyzer. SD: Standard deviation. S-QRS: Stimulated QRS duration. V6-RWPT: V6 R wave peak time. V6-V1 IPT: V6-V1 inter-peak time. Def: Definitive.

*In patients accomplishing LBBP criteria (definitive or likely).

